This phase II trial studies how well arginine works in treating patients with kidney injury
caused by anti-VEGF drugs used in standard treatment for cancer. Arginine is a nutritional
supplement that may control side effects of anti-cancer drugs such as high blood pressure and
protein in the urine and may also help to improve kidney function in patients.